

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Evaluation of the efficacy of gemfibrozil as an adjunct therapy in improving the symptoms of major depressive disorder; A double- blind, placebo-controlled trial

Protocol summary

Study aim

The objective of this study is to assess the efficacy of Gemfibrozil in the treatment of MDD

Design

Randomized double blind and placebo-controlled clinical trial

Settings and conduct

The study will be conducted among adults with major depressive disorder attending Roozbeh Hospital and Imam-Hossein Hospital(in Karaj).

Participants/Inclusion and exclusion criteria

Inclusion criteria: presence of Major Depressive Disorder based on DSM-5 criteria; baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22
Exclusion criteria: presence of psychosis, any other mental disorder; substance dependence(except for Nicotine and caffeine); IQ lower than 70;significant neurologic or medical disease; history of cholelithiasis; receiving Warfarin; receiving Insulin; receiving Statins; receiving Niacin

Intervention groups

The participants will be randomly allocated into two groups. Intervention group(20 persons) will receive gemfibrozil (300 mg per day) and sertraline (100 mg per day) for 8 weeks and control group (20 persons) will receive sertraline (100 mg per day) for 8 weeks.

Main outcome variables

Severity of depression

General information

Reason for update

change the dosage

Acronym

IRCT registration information

IRCT registration number: **IRCT20090117001556N119**
Registration date: **2019-03-17, 1397/12/26**

Registration timing: **prospective**

Last update: **2020-03-27, 1399/01/08**

Update count: **1**

Registration date

2019-03-17, 1397/12/26

Registrant information

Name

Shahin Akhondzadeh

Name of organization / entity

Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 5541 2222

Email address

s.akhond@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-04-05, 1398/01/16

Expected recruitment end date

2021-04-04, 1400/01/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the efficacy of gemfibrozil as an adjunct therapy in improving the symptoms of major depressive disorder; A double- blind, placebo-controlled trial

Public title

Evaluation of the efficacy of gemfibrozil as an adjunct therapy in improving the symptoms of major depressive disorder

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Presence of Major Depressive Disorder based on DSM-5 criteria Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22 Age between 18 to 60 years

Exclusion criteria:

Presence of psychosis Substance use disorder except for nicotine and caffeine IQ lower than 70 Any other mental disorder Any significant neurologic or medical disease(advanced renal disease, CKD, hepatic disease, cardiovascular disease) history of cholelithiasis Receiving Warfarin Receiving Insulin Receiving statins Receiving niacin

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Outcome assessor

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

Random permuted block

Blinding (investigator's opinion)

Double blinded

Blinding description

The participants, clinicians and outcome raters will be blind regarding grouping

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Tehran University of Medical Sciences

Street address

Tehran University of Medical Sciences, Keshavarz Blv

City

Tehran

Province

Tehran

Postal code

1417653761

Approval date

2019-03-08, 1397/12/17

Ethics committee reference number

IR.TUMS.VCR.REC.1397.880

Health conditions studied**1****Description of health condition studied**

Major Depressive Disorder

ICD-10 code

F32.2

ICD-10 code description

Major depressive disorder, single episode, severe without psychotic features

Primary outcomes**1****Description**

Severity of depression

Timepoint

Baseline and weeks 2,4 and 8

Method of measurement

by Hamilton Depression Rating Scale 17-Item

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: tablet sertraline 100 mg/day plus Capsule gemfibrozil 300 mg per day as intervention group for 8 weeks

Category

Treatment - Drugs

2**Description**

Control group: tablet sertraline 100 mg/day plus Capsule placebo as control group for 8 weeks

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Roozbeh Hospital

Full name of responsible person

Dr. Shahin Akhondzadeh

Street address

Roozbeh Hospital , South Kargar Sreet

City

Tehran

Province

Tehran

Postal code

1333715914

Phone

+98 21 5541 2222

Email

s.akhond@sina.tums.ac.ir

2

Recruitment center

Name of recruitment center

Imam Hossein Hospital

Full name of responsible person

Dr Atefeh Zandi Far

Street address

Imam Hossein Hospital, 104th Street, Imam Khomeini Blvd., Mohammad Shahr

City

Tehran

Province

Tehran

Postal code

3184669519

Phone

+98 26 3620 9063

Email

zandifar@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Dr. Mohammad Ali Sahraian

Street address

Keshavarz Blvd

City

Tehran

Province

Tehran

Postal code

1417653761

Phone

+98 21 8898 7381

Email

msahrai@tums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Prof. Shahin Akhondzadeh

Position

Professor of clinical psychopharmacology

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Roozbeh Hospital, South Kargar Street,

City

Tehran

Province

Tehran

Postal code

1333715914

Phone

+98 21 5541 2222

Fax

+98 21 5541 9113

Email

s.akhond@sina.tums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Prof. Shahin Akhondzadeh

Position

Professor of clinical psychopharmacology

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Roozbeh Hospital, South Kargar Street, Tehran

City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Email
s.akhond@sina.tums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Professor of clinical psychopharmacology
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Roozbeh Hospital, South Kargar Street
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Fax

+98 21 5541 9113

Email
s.akhond@sina.tums.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available

Title and more details about the data/document

The data will be distributed through final report

When the data will become available and for how long

5 years from 2021 to 2026

To whom data/document is available

Academic researchers

Under which criteria data/document could be used

by citing the resource

From where data/document is obtainable

Professor Shahin Akhondzadeh

What processes are involved for a request to access data/document

by E mail

Comments